Keyphrases
Pregnant Women
100%
Lassa Fever
96%
Meta-analysis
74%
Systematic Meta-analysis
74%
Clinical Research
64%
Lassa
55%
Bubonic Plague
49%
Plague
49%
Hospital-based Cohort
49%
Clinical Profile
49%
Ebola Virus Disease
49%
Southern Nigeria
49%
Clinical Trials
49%
Training Curriculum
37%
Disease Outbreaks
37%
Low-middle Income Countries
36%
Lassa Virus
36%
West Africa
36%
IgG Antibody
33%
Viral Hemorrhagic Fever
29%
Placental Transfer
27%
Poster Sessions
24%
Seroepidemiology
24%
Patient Data
24%
Phase III Clinical Trial
24%
Therapeutic Intervention
24%
Seroconversion
24%
Drug Development
19%
Confidence Interval
16%
Infectious Diseases
16%
Development Activities
16%
Politicians
16%
Bibliographic Databases
15%
Low Quality Data
15%
Absolute Risk
14%
Maternal Mortality
13%
Vaccine Development
12%
Course Content
12%
Course Structure
12%
Course Training
12%
Rodent Exposure
12%
Overall Satisfaction
12%
Bubo
11%
Zoonotic Disease
11%
Methodological Challenges
11%
Patient Outcomes
11%
Trial Results
11%
Optimal Treatment
11%
Pivotal Trial
11%
Clinical Endpoints
11%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
91%
Lassa Fever
87%
Infection
60%
Bubonic Plague
49%
Ebola Virus Disease
49%
Cohort Study
49%
Lassa Virus
43%
Immunoglobulin G
37%
Disease
33%
Pregnancy Disorder
24%
Seroepidemiology
24%
Case Fatality Rate
16%
Drug Development
16%
Clinical Research
16%
Maternal Antibody
12%
Zoonosis
12%
Physical Disease by Body Function
12%
Virus Hemorrhagic Fever
12%
Vaccine Development
12%
Seroprevalence
12%
Prevalence
12%
Prospective Study
10%
Maternal Death
10%
Perinatal Mortality
10%
Maternal Mortality
10%
Ribavirin
9%
Disease Course
8%
Randomized Controlled Trial
6%
Virus Infection
6%
Adverse Event
6%
Vaccine
6%
Adverse Outcome
6%
Citalopram
6%
Medicine and Dentistry
Lassa Fever
74%
Clinical Research
53%
Systematic Review
49%
Meta-Analysis
49%
Virus Infection
31%
Lassa Virus
31%
Infection
31%
Clinical Trial
29%
Low and Middle Income Countries
24%
Pregnancy Disorder
24%
Ebolavirus
24%
Seroepidemiology
24%
Cohort Analysis
24%
Seroconversion
18%
Epidemic
12%
Seroprevalence
12%
Prevalence
12%
Immunoglobulin G
12%
Prospective Study
10%
Maternal Mortality
10%
Maternal Death
10%
Perinatal Mortality
10%
Ribavirin
9%
Disease Course
8%
Consultation
7%
Randomized Controlled Trial
6%
Adverse Event
6%
Patient-Data
6%
Vaccine
6%
Attributable Risk
6%
Adverse Outcome
6%
Public Health
6%
Citalopram
6%